INTRODUCTION: Among ischemic stroke patients arriving within the treatment window, rapidly improving symptoms or having a mild deficit (i.e. too good to treat) is a common reason for exclusion. Several studies have reported poor outcomes in this group. We addressed the question of early neurological deterioration in too good to treat patients in a larger prospective cohort study. METHODS: Admission and discharge information were collected prospectively in acute stroke patients who presented to the emergency room within three-hours from onset. The primary outcome measure was change in the National Institutes of Health Stroke Scale from baseline to discharge. Secondary outcomes were discharge National Institutes of Health Stroke Scale >4, not being discharged home, and discharge modified Rankin scale. RESULTS: Of 355 patients who presented within three-hours, 127 (35·8%) had too good to treat listed as the only reason for not receiving thrombolysis, with median admission National Institutes of Health Stroke Scale = 1 (range = 0 to 19). At discharge, seven (5·5%) showed a worsening of National Institutes of Health Stroke Scale ≥1, and nine (7·1%) had a National Institutes of Health Stroke Scale >4. When excluding prior stroke (remaining n = 97), discharge status was even more benign: only five (5·2%) had a discharge National Institutes of Health Stroke Scale >4, and two (2·1%) patients were not discharged home. CONCLUSION: We found that a small proportion of patients deemed too good to treat will have early neurological deterioration, in contrast to other studies. Decisions about whether to treat mild stroke patients depend on the outcome measure chosen, particularly when considering discharge disposition among patients who have had prior stroke. The decision to thrombolyze may ultimately rest on the nature of the presentation and deficit.
INTRODUCTION: Among ischemic strokepatients arriving within the treatment window, rapidly improving symptoms or having a mild deficit (i.e. too good to treat) is a common reason for exclusion. Several studies have reported poor outcomes in this group. We addressed the question of early neurological deterioration in too good to treat patients in a larger prospective cohort study. METHODS: Admission and discharge information were collected prospectively in acute strokepatients who presented to the emergency room within three-hours from onset. The primary outcome measure was change in the National Institutes of Health Stroke Scale from baseline to discharge. Secondary outcomes were discharge National Institutes of Health Stroke Scale >4, not being discharged home, and discharge modified Rankin scale. RESULTS: Of 355 patients who presented within three-hours, 127 (35·8%) had too good to treat listed as the only reason for not receiving thrombolysis, with median admission National Institutes of Health Stroke Scale = 1 (range = 0 to 19). At discharge, seven (5·5%) showed a worsening of National Institutes of Health Stroke Scale ≥1, and nine (7·1%) had a National Institutes of Health Stroke Scale >4. When excluding prior stroke (remaining n = 97), discharge status was even more benign: only five (5·2%) had a discharge National Institutes of Health Stroke Scale >4, and two (2·1%) patients were not discharged home. CONCLUSION: We found that a small proportion of patients deemed too good to treat will have early neurological deterioration, in contrast to other studies. Decisions about whether to treat mild strokepatients depend on the outcome measure chosen, particularly when considering discharge disposition among patients who have had prior stroke. The decision to thrombolyze may ultimately rest on the nature of the presentation and deficit.
Authors: D Cocho; R Belvís; J Martí-Fàbregas; L Molina-Porcel; J Díaz-Manera; A Aleu; J Pagonabarraga; D García-Bargo; A Mauri; J-L Martí-Vilalta Journal: Neurology Date: 2005-02-22 Impact factor: 9.910
Authors: Eric E Smith; Abdul R Abdullah; Iva Petkovska; Eric Rosenthal; Walter J Koroshetz; Lee H Schwamm Journal: Stroke Date: 2005-10-06 Impact factor: 7.914
Authors: Pooja Khatri; Dawn O Kleindorfer; Sharon D Yeatts; Jeffrey L Saver; Steven R Levine; Patrick D Lyden; Charles J Moomaw; Yuko Y Palesch; Edward C Jauch; Joseph P Broderick Journal: Stroke Date: 2010-09-02 Impact factor: 7.914
Authors: D Tanne; V E Bates; P Verro; S E Kasner; J R Binder; S C Patel; H H Mansbach; S Daley; L R Schultz; P N Karanjia; P Scott; J M Dayno; K Vereczkey-Porter; C Benesch; D Book; W M Coplin; D Dulli; S R Levine Journal: Neurology Date: 1999-07-22 Impact factor: 9.910
Authors: Dawn Kleindorfer; Brett Kissela; Alex Schneider; Daniel Woo; Jane Khoury; Rosemary Miller; Kathleen Alwell; James Gebel; Jerzy Szaflarski; Arthur Pancioli; Edward Jauch; Charles Moomaw; Rakesh Shukla; Joseph P Broderick Journal: Stroke Date: 2004-01-22 Impact factor: 7.914
Authors: Christian R Baumann; Ralf W Baumgartner; Joubin Gandjour; Hans-Christian von Büdingen; Adrian M Siegel; Dimitrios Georgiadis Journal: Stroke Date: 2006-03-23 Impact factor: 7.914
Authors: Shadi Yaghi; Joshua Z Willey; Howard Andrews; Amelia K Boehme; Randolph S Marshall; Bernadette Boden-Albala Journal: Neurohospitalist Date: 2016-04-05
Authors: Meredith T Bowen; Leticia C Rebello; Mehdi Bouslama; Diogo C Haussen; Jonathan A Grossberg; Nicolas A Bianchi; Samir Belagaje; Aaron Anderson; Michael R Frankel; Raul G Nogueira Journal: Interv Neurol Date: 2017-11-23
Authors: Aleksandra Yakhkind; Ryan A McTaggart; Mahesh V Jayaraman; Matthew S Siket; Brian Silver; Shadi Yaghi Journal: Front Neurol Date: 2016-06-10 Impact factor: 4.003